For research use only. Not for therapeutic Use.
Defluoro-MDV 3100(Cat No.: C000402), also known as Defluoro-enzalutamide, is a derivative of enzalutamide, a drug used to treat prostate cancer. The compound is modified by removing a fluorine atom, potentially improving its pharmacokinetic properties, such as enhanced bioavailability and reduced side effects. Like enzalutamide, Defluoro-MDV 3100 works by inhibiting the androgen receptor, which is involved in the growth and progression of prostate cancer. Ongoing studies are evaluating its effectiveness, safety, and potential as a more efficient treatment for androgen receptor-driven cancers.
| CAS Number | 915087-16-0 |
| Synonyms | 4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-N-methylbenzamide; 4-[3-(4-Cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]-N-methylbenzamide; |
| Molecular Formula | C₂₁H₁₇F₃N₄O₂S |
| Purity | ≥95% |
| Solubility | Acetone (Slightly), Chloroform (Slightly) |
| Appearance | Pale Yellow to Light Yellow Solid |
| Storage | 4°C, Inert atmosphere |
| IUPAC Name | 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-N-methylbenzamide |
| InChI | 1S/C21H17F3N4O2S/c1-20(2)18(30)27(15-9-6-13(11-25)16(10-15)21(22,23)24)19(31)28(20)14-7-4-12(5-8-14)17(29)26-3/h4-10H,1-3H3,(H,26,29) |
| InChIKey | GOTJOTNPYGBVOP-UHFFFAOYSA-N |
| SMILES | CC1(C(=O)N(C(=S)N1C2=CC=C(C=C2)C(=O)NC)C3=CC(=C(C=C3)C#N)C(F)(F)F)C |
| Reference | Scher, H.I. et al.: Lancet, 375, 1437 (2010); Bellmunt, J. et al.: Ther. Adv. Med. Oncol., 2, 189 (2010); Ryan, C.J. et al.: J. Clin. Oncol., 29, 3651 (2011); Ma, X., et al.: J. Pharm. Biomed. Anal., 131, 436 (2016); |
